AbCellera Biologics Inc. Common Shares (ABCL) is a publicly traded Healthcare sector company. As of July 7, 2026, ABCL trades at $7.69 with a market cap of $2.48B and a P/E ratio of -16.20. ABCL moved -1.46% today. Year to date, ABCL is +128.12%; over the trailing twelve months it is +107.11%. Its 52-week range spans $1.89 to $8.42. Analyst consensus is strong buy with an average price target of $9.40. Rallies surfaces ABCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $9.40.
| Metric | Value |
|---|---|
| Price | $7.69 |
| Market Cap | $2.48B |
| P/E Ratio | -16.20 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.42 |
| 52-Week Low | $1.89 |
| Volume | 6.72M |
| Avg Volume | 0 |
| Revenue (TTM) | $79.21M |
| Net Income | $-143.96M |
| Gross Margin | 0.00% |
6 analysts cover ABCL: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.40.